Regeneron Logo.jpg
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET | Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Regeneron Logo.jpg
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
NodThera_logo.jpg
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
May 28, 2024 07:00 ET | NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
Dr. Nooristani, MD Announces Breakthrough Solution for Combatting Acidosis
Dr. Nooristani Announces Breakthrough Solution for Combatting Acidosis
May 21, 2024 09:00 ET | Balance7
Santa Maria , May 21, 2024 (GLOBE NEWSWIRE) -- Are you aware of the silent threat acidosis poses to your health? Acidosis, an imbalance in the body's pH levels, can lead to serious health issues...
Attovia-logo.jpg
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
May 09, 2024 07:30 ET | Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
May 01, 2024 08:00 ET | ImmuneSensor Therapeutics
DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...
Dr. Nooristani MD, PHYSICIAN. ENTREPRENEUR. PHILANTHROPIST. INNOVATOR. LEADER. TV HOST & CEO of Balance7
Discover Dr. Nooristani's Insights: Announcement for National Stress Awareness Month
April 18, 2024 08:00 ET | Balance7
Santa Maria , April 18, 2024 (GLOBE NEWSWIRE) -- Discover the profound impact of stress on your health during National Stress Awareness Month this April. Uncover the intricate link between...
logo.png
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 16, 2024 07:14 ET | Arch Biopartners
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a...
Nurix.png
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
April 09, 2024 07:00 ET | Nurix Therapeutics, Inc.
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14, 2024 07:57 ET | ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.